MELISSA LOCKETT: Open Payments
NPI 1801366455 · GOODYEAR, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,980 in 129 payments from 20 companies in 2025. Trend: 2023 $229 · 2024 $1,771 · 2025 $2,980
Food & beverage: $2,828Education: $152
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $765 |
| Regeneron Healthcare Solutions, Inc. | 19 | $457 |
| GENZYME CORPORATION | 14 | $348 |
| GlaxoSmithKline, LLC. | 19 | $218 |
| Insmed, Inc. | 14 | $197 |
| SANOFI-AVENTIS U.S. LLC | 2 | $152 |
| Amgen Inc. | 12 | $144 |
| Verona Pharma, Inc. | 4 | $116 |
| Actelion Pharmaceuticals US, Inc. | 3 | $90 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $88 |
Products named: DUPIXENT, FASENRA, TEZSPIRE, Arikayce, TRELEGY ELLIPTA, Ohtuvayre, NUCALA, OPSUMIT.
Industry payments across AZ — which companies pay providers there.
